Meridian Bioscience Inc. (VIVO): Price and Financial Metrics

VIVO POWR Grades

• Quality is the dimension where VIVO ranks best; there it ranks ahead of 87.15% of US stocks.
• The strongest trend for VIVO is in Growth, which has been heading down over the past 179 days.
• VIVO ranks lowest in Growth; there it ranks in the 15th percentile.

VIVO Stock Summary

• Meridian Bioscience Inc's stock had its IPO on February 26, 1992, making it an older stock than 81.81% of US equities in our set.
• Equity multiplier, or assets relative to shareholders' equity, comes in at 1.37 for Meridian Bioscience Inc; that's greater than it is for only 20.62% of US stocks.
• With a year-over-year growth in debt of -19.6%, Meridian Bioscience Inc's debt growth rate surpasses only 20.13% of about US stocks.
• If you're looking for stocks that are quantitatively similar to Meridian Bioscience Inc, a group of peers worth examining would be NSSC, SUPN, BKYI, KVHI, and IRIX.
• VIVO's SEC filings can be seen here. And to visit Meridian Bioscience Inc's official web site, go to www.meridianbioscience.com.

VIVO Valuation Summary

• VIVO's price/sales ratio is 2.9; this is 74.45% lower than that of the median Healthcare stock.
• VIVO's price/earnings ratio has moved up 21.3 over the prior 243 months.
• Over the past 243 months, VIVO's EV/EBIT ratio has gone up 16.9.

Below are key valuation metrics over time for VIVO.

VIVO Growth Metrics

Its 2 year revenue growth rate is now at -2.19%.
• Its 3 year cash and equivalents growth rate is now at 34.34%.
• Its 2 year net income to common stockholders growth rate is now at 21.71%.

Over the past 52 months, VIVO's revenue has gone up $112,549,000.

The table below shows VIVO's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2021-12-31	313.32	77.299	59.968
2021-09-30	317.896	66.865	71.407
2021-06-30	305.845	68.682	71.243
2021-03-31	327.131	73.752	87.081
2020-12-31	299.163	67.809	70.138
2020-09-30	253.667	47.976	46.186

VIVO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• VIVO has a Quality Grade of B, ranking ahead of 84.82% of graded US stocks.
• VIVO's asset turnover comes in at 0.713 -- ranking 41st of 682 Pharmaceutical Products stocks.
• CPRX, CHRS, and XTNT are the stocks whose asset turnover ratios are most correlated with VIVO.

The table below shows VIVO's key quality metrics over time.